Af­ter pulling Blenrep from US mar­kets, GSK plots a come­back with PhI­II mul­ti­ple myelo­ma tri­al suc­cess

GSK an­nounced Mon­day that its mul­ti­ple myelo­ma drug Blenrep suc­ceed­ed in a Phase III tri­al as part of a sec­ond-line com­bi­na­tion treat­ment for pa­tients whose can­cer has re­turned or stopped re­spond­ing to oth­er treat­ments.

The treat­ment had been pulled from US mar­kets last year af­ter it failed a sep­a­rate Phase III study, and in its bid to re­turn, the UK phar­ma com­pa­ny will like­ly face ques­tions around Blenrep’s ben­e­fits ver­sus risk pro­file and its mar­ket po­ten­tial.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER